These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 10353071

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients.
    Lemieux I, Salomon H, Després JP.
    Ann Med; 2003; 35(6):442-8. PubMed ID: 14572169
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia.
    Kiortisis DN, Millionis H, Bairaktari E, Elisaf MS.
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):631-5. PubMed ID: 11214768
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia.
    Melenovsky V, Malik J, Wichterle D, Simek J, Pisarikova A, Skrha J, Poledne R, Stavek P, Ceska R.
    Am Heart J; 2002 Oct; 144(4):E6. PubMed ID: 12360175
    [Abstract] [Full Text] [Related]

  • 6. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.
    Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG.
    Diabetes Care; 2002 Jul; 25(7):1198-202. PubMed ID: 12087019
    [Abstract] [Full Text] [Related]

  • 7. Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial.
    Després JP, Lemieux I, Salomon H, Delaval D.
    J Intern Med; 2002 Jun; 251(6):490-9. PubMed ID: 12028504
    [Abstract] [Full Text] [Related]

  • 8. Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia.
    Giral P, Bruckert E, Jacob N, Chapman MJ, Foglietti MJ, Turpin G.
    Atherosclerosis; 2001 Feb 01; 154(2):421-7. PubMed ID: 11166775
    [Abstract] [Full Text] [Related]

  • 9. Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia.
    Milionis HJ, Papakostas J, Kakafika A, Chasiotis G, Seferiadis K, Elisaf MS.
    J Clin Pharmacol; 2003 Aug 01; 43(8):825-30. PubMed ID: 12953339
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate.
    Ooi TC, Heinonen T, Alaupovic P, Davignon J, Leiter L, Lupien PJ, Sniderman AD, Tan MH, Tremblay G, Sorisky A, Shurzinske L, Black DM.
    Arterioscler Thromb Vasc Biol; 1997 Sep 01; 17(9):1793-9. PubMed ID: 9327779
    [Abstract] [Full Text] [Related]

  • 11. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
    Costet P, Hoffmann MM, Cariou B, Guyomarc'h Delasalle B, Konrad T, Winkler K.
    Atherosclerosis; 2010 Sep 01; 212(1):246-51. PubMed ID: 20619837
    [Abstract] [Full Text] [Related]

  • 12. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A, Comlekci A, Temiz A, Caliskan S, Ceylan C, Alacacioglu A, Yesil S.
    Metabolism; 2005 May 01; 54(5):677-81. PubMed ID: 15877299
    [Abstract] [Full Text] [Related]

  • 13. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).
    Malik J, Melenovsky V, Wichterle D, Haas T, Simek J, Ceska R, Hradec J.
    Cardiovasc Res; 2001 Nov 01; 52(2):290-8. PubMed ID: 11684077
    [Abstract] [Full Text] [Related]

  • 14. Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
    Arca M, Montali A, Pigna G, Antonini R, Antonini TM, Luigi P, Fraioli A, Mastrantoni M, Maddaloni M, Letizia C.
    Metabolism; 2007 Nov 01; 56(11):1534-41. PubMed ID: 17950105
    [Abstract] [Full Text] [Related]

  • 15. Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
    Winkler K, Weltzien P, Friedrich I, Schmitz H, Nickell HH, Hauck P, Hoffmann MM, Baumstark MW, Wieland H, März W.
    Exp Clin Endocrinol Diabetes; 2004 May 01; 112(5):241-7. PubMed ID: 15146369
    [Abstract] [Full Text] [Related]

  • 16. Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia.
    Liamis G, Kakafika A, Bairaktari E, Miltiadous G, Tsimihodimos V, Goudevenos J, Achimastos A, Elisaf M.
    Curr Med Res Opin; 2002 May 01; 18(3):125-8. PubMed ID: 12094821
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M, LCP-AtorFen Investigators.
    Clin Ther; 2009 Dec 01; 31(12):2824-38. PubMed ID: 20110022
    [Abstract] [Full Text] [Related]

  • 18. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.
    McKenney JM, McCormick LS, Weiss S, Koren M, Kafonek S, Black DM.
    Am J Med; 1998 Feb 01; 104(2):137-43. PubMed ID: 9528731
    [Abstract] [Full Text] [Related]

  • 19. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
    Christidis DS, Liberopoulos EN, Kakafika AI, Miltiadous GA, Cariolou M, Ganotakis ES, Mikhailidis DP, Elisaf MS.
    J Cardiovasc Pharmacol Ther; 2006 Sep 01; 11(3):211-21. PubMed ID: 17056835
    [Abstract] [Full Text] [Related]

  • 20. Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study.
    Insua A, Massari F, Rodríguez Moncalvo JJ, Rubén Zanchetta J, Insua AM.
    Endocr Pract; 2002 Sep 01; 8(2):96-101. PubMed ID: 11942772
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.